{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:48:58Z","timestamp":1793710138535,"version":"4.6.1"},"reference-count":142,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option beyond their established role in managing type 2 diabetes mellitus (T2DM) and obesity. Recent research has highlighted their beneficial effects on liver, kidney, and cardiovascular health, mediated by both direct and indirect mechanisms. In the liver, GLP-1 RAs contribute to the improvement of metabolic dysfunction-associated steatotic liver disease (MASLD) by reducing hepatic fat accumulation, inflammation, and oxidative stress. Additionally, they enhance insulin sensitivity and lipid metabolism. Similarly, in diabetic kidney disease (DKD), GLP-1 RAs exhibit renoprotective properties by mitigating inflammation, oxidative stress, and glomerular hypertension. Furthermore, they promote natriuresis and stabilize renal function. Moreover, GLP-1 RAs present significant cardiovascular benefits, including improved myocardial function, reduced atherosclerosis progression, enhanced endothelial health, and decreased major adverse cardiovascular events (MACEs). Additionally, emerging evidence suggests GLP-1 RAs may exert substantial neuropsychiatric benefits, including reductions in depressive symptoms, anxiety, substance use behaviors, and lowering the risk of Alzheimer\u2019s disease, Parkinson\u2019s disease, and other dementias likely mediated by the modulation of neurotransmitter systems and neuroinflammation. Genetic polymorphisms in the GLP1R gene also impact the therapeutic response, highlighting the importance of personalized medicine in optimizing GLP-1 RA efficacy. This review synthesizes preclinical and clinical evidence supporting the multifaceted effects of GLP-1 RAs across multiple organ systems, highlighting their therapeutic potential beyond glycemic control. As research advances, further exploration of their mechanisms of action and long-term clinical outcomes, safety and effectiveness across diverse patient populations will be essential in optimizing their use in treating metabolic and neuropsychiatric conditions.<\/jats:p>","DOI":"10.3390\/cimb47040285","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T20:05:56Z","timestamp":1744920356000},"page":"285","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health"],"prefix":"10.3390","volume":"47","author":[{"given":"Mohamad","family":"Al Qassab","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mneimneh","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Jradi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1391-0467","authenticated-orcid":false,"given":"Bassem","family":"Derbas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Dabboussi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Khoury Baini","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7304-168X","authenticated-orcid":false,"given":"Nadia","family":"Katrib","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Chaarani","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8491-0790","authenticated-orcid":false,"given":"Philippe","family":"Attieh","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Kanaan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5882-1619","authenticated-orcid":false,"given":"Frederic","family":"Harb","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Azar","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7983-2090","authenticated-orcid":false,"given":"Hilda E.","family":"Ghadieh","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Tripoli P.O. Box 100, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., and Zhang, Y. (2021). GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.721135"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Wilbon, S.S., and Kolonin, M.G. (2023). Glp1 Receptor Agonists-Effects Beyond Obesity and Diabetes. Cells, 13.","DOI":"10.3390\/cells13010065"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.3390\/cimb45060288","article-title":"The role of GLP1-ras in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of Nafld","volume":"45","author":"Petrovic","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). Glp-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in healthy humans: The role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metab. Clin. Exp."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"MNauck","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","unstructured":"Collins, L., and Costello, R.A. (2024). Glucagon-Like Peptide-1 Receptor Agonists, Statpearls."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/jdi.12495","article-title":"Novel extrapancreatic effects of incretin","volume":"7","author":"Yamada","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4254\/wjh.v12.i8.493","article-title":"Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update","volume":"12","author":"Sofogianni","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fang, Y., Ji, L., Zhu, C., Xiao, Y., Zhang, J., Lu, J., Yin, J., and Wei, L. (2020). Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.602574"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Toimil, A.R., and Ciudin, A. (2021). GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173955"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s40501-024-00331-y","article-title":"The impact of GLP-1 Receptor Agonists (GLP-1 ras) on Mental Health: A Systematic Review","volume":"11","author":"Valenta","year":"2024","journal-title":"Curr. Treat. Options Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hong, C.T., Chen, J.H., and Hu, C.J. (2024). Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease. J. Biomed. Sci., 31.","DOI":"10.1186\/s12929-024-01090-x"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/alz.12474","article-title":"Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists","volume":"18","author":"Yassine","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Siddeeque, N., Hussein, M.H., Abdelmaksoud, A., Bishop, J., Attia, A.S., Elshazli, R.M., Fawzy, M.S., and Toraih, E.A. (2024). Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study. Int. Immunopharmacol., 143.","DOI":"10.1016\/j.intimp.2024.113537"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/ADR-230181","article-title":"Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer\u2019s Disease: A Systematic Review","volume":"8","author":"Liang","year":"2024","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Klen, J., and Dolzan, V. (2022). Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073451"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00228-021-03249-z","article-title":"Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: A prospective cohort study","volume":"78","author":"Guan","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Maru\u0161i\u0107, M., Pai\u0107, M., Knobloch, M., and Pr\u0161o, A.-M.L. (2021). Nafld, Insulin Resistance, and Diabetes Mellitus Type 2. Can. J. Gastroenterol. Hepatol., 2021.","DOI":"10.1155\/2021\/6613827"},{"key":"ref_26","first-page":"921","article-title":"Nafld and cardiovascular diseases: A clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol. Off. J. Ger. Card. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Boccatonda, A., Andreetto, L., D\u2019Ardes, D., Cocco, G., Rossi, I., Vicari, S., Schiavone, C., Cipollone, F., and Guagnano, M.T. (2023). From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030883"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Nauck, M.A., Quast, D.R., Wefers, J., and Meier, J.J. (2021). Glp-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art. Mol. Metab., 46.","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/MCG.0000000000001556","article-title":"Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"55","author":"Jianping","year":"2021","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Nonogaki, K., and Kaji, T. (2018). Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice. J. Diabetes Res., 2018.","DOI":"10.1155\/2018\/6482958"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S2468-1253(17)30285-6","article-title":"Effects of liraglutide on weight, satiation, and gastric functions in obesity: A randomised, placebo-controlled pilot trial","volume":"2","author":"Halawi","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lee, H.A., and Kim, H.Y. (2023). Therapeutic Mechanisms and Clinical Effects of Glucagon-Like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119324"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S387116","article-title":"The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/nutrit\/nuac006","article-title":"Is calorie restriction beneficial for normal-weight individuals? A narrative review of the effects of weight loss in the presence and absence of obesity","volume":"80","author":"Magkos","year":"2022","journal-title":"Nutr. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cmet.2016.02.005","article-title":"Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity","volume":"23","author":"Magkos","year":"2016","journal-title":"Cell Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep4.1117","article-title":"Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis","volume":"2","author":"Ghadieh","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ajpath.2012.07.015","article-title":"The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis","volume":"181","author":"Gupta","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"G225","DOI":"10.1152\/ajpgi.00274.2011","article-title":"Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL\/6J mice fed a Western diet","volume":"302","author":"Mells","year":"2012","journal-title":"Am. J. Physiol. Gastrointest Liver Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.3390\/cimb44080239","article-title":"Liraglutide Exerts Protective Effects by Downregulation of PPARgamma, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis And Drug-Induced Steatosis","volume":"44","author":"Kolaric","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_42","first-page":"456","article-title":"Liraglutide alleviates lipotoxic liver cell damage and promotes autophagy to improve non-alcoholic fatty liver","volume":"29","author":"Zhang","year":"2021","journal-title":"Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chin. J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wu, Y.-R., Shi, X.-Y., Ma, C.-Y., Zhang, Y., Xu, R.-X., and Li, J.-J. (2019). Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1\/2 pathway. Cardiovasc. Diabetol., 18.","DOI":"10.1186\/s12933-019-0954-6"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-3-319-09665-0_4","article-title":"Cholesterol efflux and reverse cholesterol transport","volume":"224","author":"Favari","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"15597","DOI":"10.1073\/pnas.0405238101","article-title":"Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription","volume":"101","author":"Ishii","year":"2004","journal-title":", Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Parlevliet, E.T., Wang, Y., Geerling, J.J., der Elst, J.P.S.-V., Picha, K., O\u2019Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L.M., and Romijn, J.A. (2012). GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed apoe*3-leiden mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049152"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbrc.2018.09.134","article-title":"Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet","volume":"505","author":"Zhu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yu, L., Hong, W., Lu, S., Li, Y., Guan, Y., Weng, X., and Feng, Z. (2022). The NLRP3 inflammasome in Non-Alcoholic Fatty Liver disease and Steatohepatitis: Therapeutic Targets and Treatment. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.780496"},{"key":"ref_49","first-page":"10-29011","article-title":"Exenatide Prevents Diet-Induced Hepatocellular Injury in a CEACAM1-Dependent Mechanism","volume":"2017","author":"Ghadieh","year":"2017","journal-title":"J. Diabetes Treat"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.trsl.2016.08.006","article-title":"Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress","volume":"180","author":"Li","year":"2017","journal-title":"Transl. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00281-013-0407-3","article-title":"Ceacam1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH)","volume":"36","author":"Najjar","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1309\/6VJ4DWGYDU0XYJ8Q","article-title":"Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease","volume":"127","author":"Manco","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Heinrich, G., Ghadieh, H.E., Ghanem, S.S., Muturi, H.T., Rezaei, K., Al-Share, Q.Y., Bowman, T.A., Zhang, D., Garofalo, R.S., and Yin, L. (2017). Loss of Hepatic CEACAM1: A Unifying Mechanism Linking Insulin Resistance to Obesity and Non-Alcoholic Fatty Liver Disease. Front. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00008"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1080\/21655979.2022.2036902","article-title":"Liraglutide inhibits receptor for advanced glycation end products (RAGE)\/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro","volume":"13","author":"Ji","year":"2022","journal-title":"Bioengineered"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1507\/endocrj.EJ16-0449","article-title":"Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: A randomized control trial","volume":"64","author":"Bouchi","year":"2017","journal-title":"Endocr. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1172\/JCI8814","article-title":"CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis","volume":"105","author":"Leclercq","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Gluud, L.L., Knop, F.K., and Vilsb\u00f8ll, T. (2014). Effects of lixisenatide on elevated liver transaminases: Systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open, 4.","DOI":"10.1136\/bmjopen-2014-005325"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/dmrr.2561","article-title":"Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes","volume":"30","author":"Shao","year":"2014","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: Randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Ghosal, S., Datta, D., and Sinha, B. (2021). A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci. Rep., 11.","DOI":"10.1038\/s41598-021-01663-y"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults with Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.23876\/j.krcp.22.001","article-title":"Glp-1 receptor agonists in diabetic kidney disease: Current evidence and future directions","volume":"41","author":"Yu","year":"2022","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/jdi.12956","article-title":"Protein kinase c and protein kinase a are involved in the protection of recombinant human glucagon-like peptide-1 on glomeruli and tubules in diabetic rats","volume":"10","author":"Yin","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Kim, J.-W., Park, S.-Y., You, Y.-H., Ham, D.-S., Lee, S.-H., Yang, H.K., Jeong, I.-K., Ko, S.-H., and Yoon, K.-H. (2016). Suppression of ROS Production by Exendin-4 in PSC Attenuates the High Glucose-Induced Islet Fibrosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163187"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., and LeRoith, D. (2023). Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.orcp.2019.03.003","article-title":"Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-\u03b1-mediated NF-\u03baB and MAPK pathway","volume":"13","author":"Ye","year":"2019","journal-title":"Obes. Res. Clin. Pract."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.2337\/db17-1212","article-title":"Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy","volume":"67","author":"Moellmann","year":"2018","journal-title":"Diabetes"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"C572","DOI":"10.1152\/ajpcell.00093.2016","article-title":"Activation of NRF2 contributes to the protective effect of Exendin-4 against angiotensin II-induced vascular smooth muscle cell senescence","volume":"311","author":"Zhou","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1159\/000366307","article-title":"Activation of the Nrf2-ARE pathway attenuates hyperglycemia-mediated injuries in mouse podocytes","volume":"34","author":"Wang","year":"2014","journal-title":"Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1210\/jc.2014-2291","article-title":"Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: A prospective pilot study","volume":"100","author":"Rizzo","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Farah, L.X.S., Valentini, V., Pessoa, T.D., Malnic, G., McDonough, A.A., and Girardi, A.C.C. (2016). The physiological role of glucagon-like peptide-1 in the regulation of renal function. Am. J. Physiol. Ren. Physiol., 310.","DOI":"10.1152\/ajprenal.00394.2015"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"van Baar, M.J.B., van der Aart, A.B., Hoogenberg, K., Joles, J.A., Heerspink, H.J.L., and van Raalte, D.H. (2019). The incretin pathway as a therapeutic target in diabetic kidney disease: A clinical focus on GLP-1 receptor agonists. Ther. Adv. Endocrinol. Metab., 10.","DOI":"10.1177\/2042018819865398"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Puglisi, S., Rossini, A., Poli, R., Dughera, F., Pia, A., Terzolo, M., and Reimondo, G. (2021). Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.738848"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12651","article-title":"Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: A randomized clinical trial","volume":"18","author":"Skov","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Ronn, J., Jensen, E.P., Albrechtsen, N.J.W., Holst, J.J., and Sorensen, C.M. (2017). Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors. Physiol. Rep., 5.","DOI":"10.14814\/phy2.13503"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ajh\/hpt196","article-title":"Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: Results of a systematic meta-analysis and meta-regression","volume":"27","author":"Katout","year":"2014","journal-title":"Am. J. Hypertens."},{"key":"ref_83","first-page":"T1","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS","volume":"221","author":"Kulve","year":"2014","journal-title":"J. Endocrinol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"Khunti","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients with Type 2 Diabetes: Pooled Analysis of Sustain 6 and Leader","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/ccr3.4022","article-title":"Effects of concomitant combination of sglt-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with EGFR below 30 and macroalbuminuria: A case series","volume":"9","author":"Kuhadiya","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s13730-019-00379-3","article-title":"Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor","volume":"8","author":"Morino","year":"2019","journal-title":"CEN Case Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40265-013-0033-3","article-title":"Lixisenatide: First global approval","volume":"73","author":"Elkinson","year":"2013","journal-title":"Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"Glp-1 receptor agonists (GLP-1RAs): Cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_91","first-page":"57","article-title":"Liraglutide directly protects cardiomyocytes against reperfusion injury possibly via modulation of intracellular calcium homeostasis","volume":"14","author":"Hu","year":"2017","journal-title":"J. Geriatr. Cardiol. JGC"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1536\/ihj.19-327","article-title":"Exendin-4 Reduces Ventricular Arrhythmia Activity and Calcium Sparks-Mediated Sarcoplasmic Reticulum Ca Leak in Rats with Heart Failure","volume":"61","author":"Chen","year":"2020","journal-title":"Int. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 Receptor Expression Within the Human Heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Li, J., Liu, X., Fang, Q., Ding, M., and Li, C. (2017). Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats. Diabetol. Metab. Syndr., 9.","DOI":"10.1186\/s13098-017-0289-y"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Di Tomo, P., Lanuti, P., Di Pietro, N., Baldassarre, M.P.A., Marchisio, M., Pandolfi, A., Consoli, A., and Formoso, G. (2017). Liraglutide mitigates TNF-\u03b1 induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women. Diabetes\/Metab. Res. Rev., 33.","DOI":"10.1002\/dmrr.2925"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Wei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., Liu, Y., Hou, W., Feng, X., and Wang, G. (2016). Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner, American Journal of Physiology. Endocrinol. Metab., 310.","DOI":"10.1152\/ajpendo.00400.2015"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Kitade, H., Chen, G., Ni, Y., and Ota, T. (2017). Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients, 9.","DOI":"10.3390\/nu9040387"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The Global Epidemiology of Diabetes and Kidney Disease","volume":"25","author":"DKoye","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Cai, X., Yang, W., Gao, X., Zhou, L., Han, X., and Ji, L. (2016). Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166625"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/dom.14160","article-title":"Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Harmony Outcomes and investigators, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMcp2000280","article-title":"Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes","volume":"384","author":"Kalyani","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/dom.14108","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis","volume":"22","author":"Mantsiou","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcjd.2019.09.003","article-title":"Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults with Type 2 Diabetes Mellitus","volume":"44","author":"Sharma","year":"2020","journal-title":"Can. J. Diabetes"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Vi, N.B., Tressler, E.H., Vendruscolo, L.F., Leggio, L., and Farokhnia, M. (2024). Iuphar review\u2014Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacol. Res., 207.","DOI":"10.1016\/j.phrs.2024.107312"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","article-title":"GLP-1 and weight loss: Unraveling the diverse neural circuitry","volume":"310","author":"Kanoski","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_114","first-page":"263","article-title":"Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines","volume":"7","author":"Ventorp","year":"2017","journal-title":"J. Park. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Yang, F., Wang, X., Qi, J., Zhang, K., Jiang, Y., Feng, B., Lv, T., Yang, L., Yang, Q., and Zhao, M. (2022). Glucagon-Like Peptide 1 Receptor Activation Inhibits Microglial Pyroptosis via Promoting Mitophagy to Alleviate Depression-Like Behaviors in Diabetic Mice. Nutrients, 15.","DOI":"10.3390\/nu15010038"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Tsai, W.H., Sung, F.C., Chiu, L.T., Shih, Y.H., Tsai, M.C., and Wu, S.I. (2022). Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.765446"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euroneuro.2024.07.001","article-title":"Glp-1 agonists and risk of suicidal thoughts and behaviours: Confound by indication once again? A narrative review","volume":"87","author":"Strumila","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Monney, M., Jornayvaz, F.R., and Gariani, K. (2023). Glp-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes Metab., 49.","DOI":"10.1016\/j.diabet.2023.101470"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Yaribeygi, H., Rashidy-Pour, A., Atkin, S.L., Jamialahmadi, T., and Sahebkar, A. (2021). Glp-1 mimetics and cognition. Life Sci., 264.","DOI":"10.1016\/j.lfs.2020.118645"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Darwish, A.B., El Sayed, N.S., Salama, A.A.A., and Saad, M.A. (2023). Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL\/6 mice: Implications on GLP-1R and CAMP\/PKA signaling pathway in the hippocampus. Life Sci., 320.","DOI":"10.1016\/j.lfs.2023.121546"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"112","DOI":"10.12659\/MSMBR.891168","article-title":"Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes","volume":"20","author":"Celikyurt","year":"2014","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00125-024-06243-z","article-title":"Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: A propensity-weighted, population-based cohort study","volume":"67","author":"Hurtado","year":"2024","journal-title":"Diabetologia"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Martinelli, S., Mazzotta, A., Longaroni, M., and Petrucciani, N. (2024). Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials. Drug Alcohol. Depend., 264.","DOI":"10.1016\/j.drugalcdep.2024.112424"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ADM.0000000000001347","article-title":"The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review","volume":"18","author":"Shen","year":"2024","journal-title":"J. Addict. Med."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Du, H., Meng, X., Yao, Y., and Xu, J. (2022). The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1033479"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Pelle, M.C., Zaffina, I., Giofre, F., Pujia, R., and Arturi, F. (2023). Potential Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411301"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s11095-022-03302-1","article-title":"Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative Diseases: A narrative Review","volume":"39","author":"Mahapatra","year":"2022","journal-title":"Pharm. Res."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Holscher, C. (2024). Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson\u2019s and Alzheimer\u2019s disease clinical trials: A revolution in the making?. Neuropharmacology, 253.","DOI":"10.1016\/j.neuropharm.2024.109952"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Tseng, P.T., Zeng, B.Y., Hsu, C.W., Hung, C.M., Carvalho, A.F., Stubbs, B., Chen, Y.W., Chen, T.Y., Lei, W.T., and Chen, J.J. (2025). The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: Evidence from a network meta-analysis. BMC Med., 23.","DOI":"10.1186\/s12916-025-04018-w"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Norgaard, C.H., Friedrich, S., Hansen, C.T., Gerds, T., Ballard, C., Moller, D.V., Knudsen, L.B., Kvist, K., Zinman, B., and Holm, E. (2022). Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement., 8.","DOI":"10.1002\/trc2.12268"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: An exploratory analysis of the REWIND trial","volume":"19","author":"Gerstein","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Gejl, M., Gjedde, A., Egefjord, L., Moller, A., Hansen, S.B., Vang, K., Rodell, A., Braendgaard, H., Gottrup, H., and Schacht, A. (2016). In Alzheimer\u2019s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Front. Aging Neurosci., 8.","DOI":"10.3389\/fnagi.2016.00108"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00032.2015","article-title":"Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans","volume":"96","author":"Kullmann","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12325-023-02761-1","article-title":"Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus","volume":"41","author":"Eghbali","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1089\/dna.2020.5424","article-title":"Glp1r Single-Nucleotide Polymorphisms rs3765467 and rs10305492 Affect Beta Cell Insulin Secretory Capacity and Apoptosis through GLP-1","volume":"39","author":"Li","year":"2020","journal-title":"DNA Cell Biol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1017\/neu.2020.14","article-title":"Association between GLP-1 receptor gene polymorphisms with reward learning, anhedonia and depression diagnosis","volume":"32","author":"Appadurai","year":"2020","journal-title":"Acta Neuropsychiatr."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40618-014-0161-y","article-title":"Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naive type 2 diabetic patients","volume":"38","author":"Aller","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1210\/clinem\/dgad290","article-title":"Rare Heterozygous Loss-Of-Function Variants in the Human GLP-1 Receptor Are Not Associated with Cardiometabolic Phenotypes","volume":"108","author":"Melchiorsen","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Ma, X., Lu, R., Gu, N., Wei, X., Bai, G., Zhang, J., Deng, R., Feng, N., Li, J., and Guo, X. (2018). Polymorphisms in the Glucagon-Like Peptide 1 Receptor (GLP-1R) Gene Are Associated with the Risk of Coronary Artery Disease in Chinese Han Patients with Type 2 Diabetes Mellitus: A Case-Control Study. J. Diabetes Res., 2018.","DOI":"10.1155\/2018\/1054192"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jdiacomp.2015.02.010","article-title":"Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor","volume":"29","author":"Soto","year":"2015","journal-title":"J. Diabetes Complicat."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Chedid, V., Vijayvargiya, P., Carlson, P., Van Malderen, K., Acosta, A., Zinsmeister, A., and Camilleri, M. (2018). Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study. Neurogastroenterol. Motil., 30.","DOI":"10.1111\/nmo.13313"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00228-015-1868-1","article-title":"Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: A pilot study","volume":"71","author":"Jensterle","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/4\/285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:16:28Z","timestamp":1760030188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/4\/285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":142,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cimb47040285"],"URL":"https:\/\/doi.org\/10.3390\/cimb47040285","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}